Join us in San Francisco for the 2nd Annual Drug Repositioning Conference, where presenters and panelists will share with the audience best practices, new technologies, case studies, and regulatory developments in drug repositioning and indications discovery.

The 2nd Annual Drug Repositioning Conference, to be held on October 23-24, 2012 in San Francisco, CA will feature a variety of speakers from academia, industry, non-profits and government. Their perspectives will provide insight into the field of drug repositioning and the challenges and successes in getting a repositioned drug to the marketplace. Building on last year’s conference, the 2nd Annual Drug Repositioning Conference will discuss what has changed in the last year and what continues to drive interest in drug repositioning. Case studies will give attendees concrete examples of successfully repositioned drugs and there will be a focus on the best pathway to success for repositioning drugs.

About Drug Repositioning & Indications Discovery
Since the development of new drugs can be time consuming and expensive, drug repositioning has emerged as a potentially cost-effective and quicker alternative to provide new drugs for pharmaceutical companies’ waning pipelines. Approved drugs have already met with the FDA’s approval therefore, the early stages of drug development can be bypassed. By mining existing drugs for new uses, researchers can focus instead on the clinical testing portion of the process. This shortens the development timeline and gets new treatments to patients faster. With new technologies and approaches, drug repositioning has become more streamlined and less accidental than it was in the past. By using a more systematic approach, existing compounds are being tested for both common and neglected diseases faster and with more success.

At the conference, we will highlight the following topics